Gene · 5683
PSMA2: proteasome 20S subunit alpha 2
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. PSMA2: proteasome 20S subunit alpha 2. Genes, record 5683. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/5683
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P25787 | Proteasome subunit alpha type-2 | 234 | 177 | Ensembl, GeneID, HGNC |
Source UniProt
Patents41
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 59503 | P25787 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 594 | P25787 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 594 | P25787 | Espacenet |
| JP 2024009871 A | 2024-01-23 | 15 | P25787 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 67852 | P25787 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 75660 | P25787 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 170823 | P25787 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 178631 | P25787 | Espacenet |
| KR 1020210152990 A | 2021-12-16 | 5 | P25787 | Espacenet |
| KR 1020210111195 A | 2021-09-10 | 5 | P25787 | Espacenet |
1 to 10 of 41
See all 41 patentsDrugs7
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| BORTEZOMIB | CHEMBL325041 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| BORTEZOMIB D-MANNITOL | CHEMBL5315122 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| CARFILZOMIB | CHEMBL451887 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| IXAZOMIB | CHEMBL2141296 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| IXAZOMIB CITRATE | CHEMBL3545432 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| MARIZOMIB | CHEMBL371405 | 20S proteasome inhibitor | INHIBITOR | ChEMBL |
| OPROZOMIB | CHEMBL2103884 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
Trials1,241
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07605416 | CARFILZOMIB | PHASE2 | ClinicalTrials.gov | |
| NCT07601100 | BORTEZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07600151 | BORTEZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07513129 | BORTEZOMIB | PHASE1 | ClinicalTrials.gov | |
| NCT07479979 | CARFILZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07464210 | BORTEZOMIB | PHASE2 | ClinicalTrials.gov | |
| NCT07463807 | CARFILZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07428369 | BORTEZOMIB | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT07391657 | BORTEZOMIB | PHASE3 | ClinicalTrials.gov | |
| NCT07391657 | CARFILZOMIB | PHASE3 | ClinicalTrials.gov |
1 to 10 of 1,241
See all 1,241 trialsNIH grants539
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | PSMA2 papers | Newest fiscal year |
|---|---|---|---|
| R01AG011085 | Ubiquitin‐mediated proteolysis and cell cycle control | 8 | 2025 |
| ZIAAI000904 | Staphylococcal pathogenesis | 6 | 2025 |
| P30CA016058 | Cancer Center Support Grant | 3 | 2025 |
| P30AI027763 | UCSF-Bay Area Center for AIDS Research | 2 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 2 | 2025 |
| P50CA168504 | Dana Farber/Harvard Cancer Center Specialized Program of Research Excellence in Breast Cancer | 2 | 2025 |
| P50CA186781 | Mayo Clinic Multiple Myeloma SPORE | 2 | 2025 |
| K08AI151265 | Functions for novel IL-15-responsive macrophages in the uterus during pregnancy | 1 | 2025 |
| K12EY022299 | Michigan Vision Clinician Scientist Development Program | 1 | 2025 |
| P01AG026276 | Antecedent Biomarkers for Alzheimer Disease: The Adult Children Study | 1 | 2025 |
1 to 10 of 539Source NIH's project files
See all 539 nih grantsPapers707
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Discovery of hub genes linking oxidative stress to type 2 diabetic sarcopenia using single-cell sequencing and machine learning. | PLoS One | 2026 | 42412755 | PubTator, text mining | PubMed |
| Circulating cell type senescence signatures track distinct dimensions of health status and trajectories in human longitudinal cohorts. | Cell Rep | 2026 | 42276069 | PubTator, text mining | PubMed |
| Analysis of core target genes of vagus nerve stimulation in epilepsy, ischemic stroke, and depression: Separate insights from network pharmacology, bioinformatics, and Mendelian randomization. | Medicine (Baltimore) | 2026 | 42071808 | PubTator, text mining | PubMed |
| Integrative analysis of the PSMA family identifies PSMA6 as an adverse prognostic biomarker promoting bladder cancer cell proliferation. | Int J Med Sci | 2026 | 41799753 | PubTator, text mining | PubMed |
| Identification of multigene predictors of prognosis in patients with ovarian cancer. | iScience | 2026 | 41767263 | PubTator, text mining | PubMed |
| Takotsubo Syndrome: The First Non-Acute Proteomic Analysis by Remote Dried Blood Microsampling. | J Cardiovasc Transl Res | 2026 | 41760974 | PubTator, text mining | PubMed |
| Circulating Cell Type Senescence Signatures Reveal High-Resolution Health Status and Trajectories in Human Longitudinal Studies. | medRxiv | 2026 | 41728302 | PubTator, text mining | PubMed |
| PRRSV Nsp12 targets PSMA2 to suppress host proteasome activity and promote viral survival. | Vet Microbiol | 2026 | 41475191 | PubTator, text mining | PubMed |
| Prognostic Value and Immune Characterization of Genes Associated with Childhood Acute Leukemia applying Single-Cell RNA Sequencing. | Endocr Metab Immune Disord Drug Targets | 2026 | 40910197 | PubTator, text mining | PubMed |
| METTL14 Regulates the Expression of Genes Related to Interferon, Interleukin and MHC Class I in Nasopharyngeal Carcinoma Cells. | Cancer Med | 2025 | 41316520 | PubTator, text mining | PubMed |
1 to 10 of 707
See all 707 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/5683
GET https://conductscience.org/api/genes/v1/5683/patents?page=2